Biomarkers vs. pen-and-paper tests for Alzheimer's: which wins?

If you just go by the headlines, you'd think that the science of biomarkers had taken another hit. "Alzheimer's tests using pen and paper still the best," says the Booster Shots blog in the Los Angeles Times; "Biomarkers Flunk Alzheimer's Test," says MedPage Today. But if you read the articles, and the paper in the Archives of General Psychiatry on which they are based, you'd see that the proverbial apples are being compared with oranges. Biomarkers may, indeed, be best for early, presymptomatic Alzheimer's disease, while old-fashioned pen-and-paper cognitive tests are not only biomarkers for the degenerative neurological disease, but are used to diagnose it in the first place.

The authors took a close look at 116 people with mild cognitive impairment who later developed Alzheimer's, along with 204 who did not develop the disease and 197 cognitively healthy people. They ran the whole battery of tests on them, including pen-and-paper tests, spinal fluid and blood tests, plus brain scans. They found that two cognitive tests more-accurately predicted whether a patient would develop Alzheimer's than did any changes in biomarkers.

However, the study's authors added that biomarkers "may be most informative in very early prodromal stages, a perspective that has been incorporated into proposed diagnostic criteria for preclinical AD." They continue: "One might argue that the use of cognitive markers in this context is a tautology because they are used in the diagnosis of [Alzheimer's disease] itself." So, they say, cognitive markers offer an advantage over biomarkers because they cost less and take up less time, among other things, they also are more likely to predict Alzheimer's simply because measurable cognitive impairment is a criteria for diagnosing the disease in the first place.

This still leaves room for biomarkers as a predictor before cognitive impairment is measurable by pen-and-paper tests.

- read the story in the Booster Shots blog
- MedPage Today filed this report
- here's another story from Internal Medicine News
- and read the abstract in the Archives of General Psychiatry

Suggested Articles

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.